T2 Biosystems, Inc.
TTOO · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | 0.08 | 0.04 |
| FCF Yield | -294.85% | -703.74% | -47.98% | -29.26% |
| EV / EBITDA | -1.14 | -1.02 | -2.87 | -5.19 |
| Quality | ||||
| ROIC | -230.51% | -200.41% | -85.90% | -57.78% |
| Gross Margin | -113.58% | 5.23% | 26.21% | -17.37% |
| Cash Conversion Ratio | 0.96 | 0.82 | 0.79 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -36.47% | 7.15% | 49.87% | 19.97% |
| Free Cash Flow Growth | 5.18% | -29.58% | 10.64% | 4.56% |
| Safety | ||||
| Net Debt / EBITDA | -0.77 | -0.89 | -0.88 | -1.09 |
| Interest Coverage | -9.30 | -8.88 | -5.66 | -7.51 |
| Efficiency | ||||
| Inventory Turnover | 3.19 | 4.86 | 5.30 | 5.85 |
| Cash Conversion Cycle | 150.27 | 88.11 | 85.77 | 129.72 |